Last reviewed · How we verify

NCT04214106

Thiamine Administration and Prevalence of Delirium in the Intensive Care Unit: A Before-after Study

Completed Last updated 24 February 2021
What this trial tests

trial testing intravenous Thiamine in Delirium in 1,000 participants. Completed in 1 January 2021.

Timeline
19 February 2020
Primary endpoint
1 December 2020
1 January 2021

Quick facts

Lead sponsorMeir Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,000
Start date19 February 2020
Primary completion1 December 2020
Estimated completion1 January 2021
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Meir Medical Center

Who can join

Adults 18 to 99, any sex, with Delirium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Delirium is a very common condition among ICU-admitted patients, and its prevalence is estimated between 30-40%. Delirium is associated with increased morbidity and mortality and future cognitive decline, along with increased ventilation-dependency and other complications. There are multiple risk factors for delirium, including deficiencies of micronutrients. Thiamine deficiency is associated with specific neurological syndromes, including Wernicke and Korsakoff syndromes and Delirium Tremens. Several studies demonstrated significant thiamine deficiency among ICU-admitted patients (prevalence of 30-70%) without known risk factors, such as alcohol dependency. Thiamine deficiency may cause delirium in those patients. Intravenous thiamine had been safely used for decades, for several indications. Lately, thiamine has been advocated for therapy in patients with septic shock, and its use in intensive care units has increased worldwide. Since 2016, thiamine has been routinely administered in our intensive care unit. Considering the theoretical association between thiamine deficiency and ICU-related delirium, the investigators aim to investigate whether the routine use of thiamine has been associated with decreased prevalence of delirium among ICU patients when compared to the pre-routine thiamine administration era.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Delirium in Critical Illness Patients and the Potential Role of Thiamine Therapy in Prevention and Treatment: Findings from a Scoping Review with Implications for Evidence-Based Practice.
    Lange S, Mędrzycka-Dąbrowska W, Friganovic A, Oomen B, et al · · 2021 · cited 8× · PMID 34444556 · DOI 10.3390/ijerph18168809

Verify or expand the search:

Other recruiting trials for Delirium

Currently open trials in the same condition.

Other Meir Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04214106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing